The European Commission (EC) has approved Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) plus the ...

Takeda Pharmaceutical Company Limited (NYSE:TAK)’s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized ...

The drug has been approved in combination with the chemotherapy regimen etoposide, cyclophosphamide, doxorubicin, dacarbazine ...

"I am extremely proud that Takeda has been recognized as one of the top ten employers in the world for 2024. This confirms ...

Osaka: Takeda has received approval from the European Commission (EC) for ADCETRIS (brentuximab vedotin) in combination with ...

Takeda (NYSE:TAK) (4502.T) said on Monday that the European Commission approved Pfizer (NYSE:PFE) and the company's ...

This is the web version of STAT’s special newslette r from the annual meeting of the American Society of Oncology. For more ...

The first half of this year has been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...

We are pleased to partner with Takeda as we continue to advance rusfertide to potentially transform the standard of care in PV patients around the world.” “These promising pivotal data ...

1, Polly Mack, 290.28. 2, Julia Lopez Ramirez, 286.77. 3, Auston Kim, 285.76. 4, Emily Kristine Pedersen, 283.34. 5, Weiwei Zhang, 281.13. 6, Maude-Aimee Leblanc, 278.68. 7, Bailey Tardy, 278.42. 8, ...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., June 01, 2025--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502 ...